{"transactions":[{"id":701493,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T20:15:04.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":5388,"price":26.0428,"value":140318.6064,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.00 to $26.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 3) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3586796,"source":{"system":"sec-edgar","filing":"0001193125-26-323754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526323754/ownership.xml","form_type":"4"}},{"id":701492,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-29T20:15:04.000Z","date":"2026-07-27","kind":"sale","planned":true,"acquired":false,"shares":256072,"price":25.5024,"value":6530450.5728,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $25.00 to $25.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,160,426 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 3) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3592184,"source":{"system":"sec-edgar","filing":"0001193125-26-323754","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526323754/ownership.xml","form_type":"4"}},{"id":727770,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:27:26.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":1657,"price":21.4742,"value":35582.7494,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $21.45 to $21.495, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3848256,"source":{"system":"sec-edgar","filing":"0001193125-26-281119","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526281119/ownership.xml","form_type":"4"}},{"id":727769,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:27:26.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":71629,"price":21.0357,"value":1506766.1553,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.45 to $21.44, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3849913,"source":{"system":"sec-edgar","filing":"0001193125-26-281119","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526281119/ownership.xml","form_type":"4"}},{"id":727768,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-24T20:27:26.000Z","date":"2026-06-22","kind":"sale","planned":true,"acquired":false,"shares":190676,"price":20.5703,"value":3922262.5228,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.13 to $20.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,421,886 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":3921542,"source":{"system":"sec-edgar","filing":"0001193125-26-281119","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526281119/ownership.xml","form_type":"4"}},{"id":730628,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:15:03.000Z","date":"2026-06-18","kind":"sale","planned":true,"acquired":false,"shares":46901,"price":20.0715,"value":941373.4215,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,685,848 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4112218,"source":{"system":"sec-edgar","filing":"0001193125-26-277529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526277529/ownership.xml","form_type":"4"}},{"id":730627,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-22T20:15:03.000Z","date":"2026-06-17","kind":"sale","planned":true,"acquired":false,"shares":37454,"price":20.1398,"value":754316.0692,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,685,848 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4159119,"source":{"system":"sec-edgar","filing":"0001193125-26-277529","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526277529/ownership.xml","form_type":"4"}},{"id":744759,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-09T21:12:56.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":35152,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35152,"derivative":{"exercise_price":17.04,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":35152},"source":{"system":"sec-edgar","filing":"0001193125-26-264021","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526264021/ownership.xml","form_type":"4"}},{"id":801910,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-23T20:15:03.000Z","date":"2026-04-22","kind":"sale","planned":true,"acquired":false,"shares":2652,"price":20.0035,"value":53049.282,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,770,203 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4196573,"source":{"system":"sec-edgar","filing":"0001193125-26-173736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526173736/ownership.xml","form_type":"4"}},{"id":801909,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-23T20:15:03.000Z","date":"2026-04-21","kind":"sale","planned":true,"acquired":false,"shares":8300,"price":20.0145,"value":166120.35,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,770,203 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4199225,"source":{"system":"sec-edgar","filing":"0001193125-26-173736","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526173736/ownership.xml","form_type":"4"}},{"id":803776,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T20:15:06.000Z","date":"2026-04-20","kind":"sale","planned":true,"acquired":false,"shares":125274,"price":20.0672,"value":2513898.4128,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $21.00 to $21.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,781,155 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4207525,"source":{"system":"sec-edgar","filing":"0001193125-26-166822","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526166822/ownership.xml","form_type":"4"}},{"id":803775,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-21T20:15:06.000Z","date":"2026-04-17","kind":"sale","planned":true,"acquired":false,"shares":211974,"price":20.2916,"value":4301291.6184,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 2,781,155 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4332799,"source":{"system":"sec-edgar","filing":"0001193125-26-166822","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526166822/ownership.xml","form_type":"4"}},{"id":805737,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-17T20:05:04.000Z","date":"2026-04-16","kind":"sale","planned":true,"acquired":false,"shares":6657,"price":20.0575,"value":133522.7775,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,118,403 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4544773,"source":{"system":"sec-edgar","filing":"0001193125-26-161508","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526161508/ownership.xml","form_type":"4"}},{"id":805736,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-17T20:05:04.000Z","date":"2026-04-16","kind":"sale","planned":true,"acquired":false,"shares":11116,"price":21.1039,"value":234590.9524,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $21.00 to $21.345, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,118,403 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4551430,"source":{"system":"sec-edgar","filing":"0001193125-26-161508","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526161508/ownership.xml","form_type":"4"}},{"id":805735,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-04-17T20:05:04.000Z","date":"2026-04-15","kind":"sale","planned":true,"acquired":false,"shares":81840,"price":20.2718,"value":1659044.112,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.00 to $20.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,118,403 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4562546,"source":{"system":"sec-edgar","filing":"0001193125-26-161508","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526161508/ownership.xml","form_type":"4"}},{"id":844032,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-13T20:35:44.000Z","date":"2026-03-11","kind":"sale","planned":true,"acquired":false,"shares":129672,"price":19.5151,"value":2530562.0472,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.88 to $19.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,218,016 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4644386,"source":{"system":"sec-edgar","filing":"0001193125-26-106269","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526106269/ownership.xml","form_type":"4"}},{"id":848811,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-11T21:27:17.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":281858,"price":19.8001,"value":5580816.5858,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $19.61 to $20.03, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,347,688 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":4774058,"source":{"system":"sec-edgar","filing":"0001193125-26-102469","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526102469/ownership.xml","form_type":"4"}},{"id":848810,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-11T21:27:17.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":219758,"price":19.325,"value":4246823.35,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.61 to $19.605, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,347,688 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5055916,"source":{"system":"sec-edgar","filing":"0001193125-26-102469","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526102469/ownership.xml","form_type":"4"}},{"id":848809,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-11T21:27:17.000Z","date":"2026-03-10","kind":"sale","planned":true,"acquired":false,"shares":9482,"price":18.2121,"value":172687.1322,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $17.595 to $18.59, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,347,688 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5275674,"source":{"system":"sec-edgar","filing":"0001193125-26-102469","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526102469/ownership.xml","form_type":"4"}},{"id":848808,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-03-11T21:27:17.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":177690,"price":17.7218,"value":3148986.642,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by ForDyne B.V. (\"ForDyne\") on November 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $17.50 to $18.21, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by ForDyne. ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,347,688 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5285156,"source":{"system":"sec-edgar","filing":"0001193125-26-102469","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526102469/ownership.xml","form_type":"4"}},{"id":1125255,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-04T01:38:43.000Z","date":"2025-05-30","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 30, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 30, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":35000,"derivative":{"exercise_price":11.96,"expiration_date":"2035-05-29","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0000950170-25-081355","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025081355/ownership.xml","form_type":"4"}},{"id":1337308,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-10T21:05:03.000Z","date":"2024-12-09","kind":"sale","planned":false,"acquired":false,"shares":34437,"price":29.18,"value":1004871.66,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.66, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by ForDyne B.V. (\"ForDyne\"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,974,175 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5400545,"source":{"system":"sec-edgar","filing":"0000950170-24-134961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024134961/ownership.xml","form_type":"4"}},{"id":1337307,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-10T21:05:03.000Z","date":"2024-12-06","kind":"sale","planned":false,"acquired":false,"shares":101675,"price":29.34,"value":2983144.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.565, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by ForDyne B.V. (\"ForDyne\"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 3,974,175 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5434982,"source":{"system":"sec-edgar","filing":"0000950170-24-134961","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024134961/ownership.xml","form_type":"4"}},{"id":1340574,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-06T21:05:16.000Z","date":"2024-12-05","kind":"sale","planned":false,"acquired":false,"shares":3806,"price":29.05,"value":110564.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.365, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by ForDyne B.V. (\"ForDyne\"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 4,110,287 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5536657,"source":{"system":"sec-edgar","filing":"0000950170-24-134076","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024134076/ownership.xml","form_type":"4"}},{"id":1340573,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-06T21:05:16.000Z","date":"2024-12-04","kind":"sale","planned":false,"acquired":false,"shares":135039,"price":29.39,"value":3968796.21,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by ForDyne B.V. (\"ForDyne\"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 4,110,287 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5540463,"source":{"system":"sec-edgar","filing":"0000950170-24-134076","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024134076/ownership.xml","form_type":"4"}},{"id":1343149,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-04T21:05:12.000Z","date":"2024-12-03","kind":"sale","planned":false,"acquired":false,"shares":29732,"price":29.05,"value":863714.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.00 to $29.25, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by ForDyne B.V. (\"ForDyne\"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 4,249,132 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5675502,"source":{"system":"sec-edgar","filing":"0000950170-24-133233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024133233/ownership.xml","form_type":"4"}},{"id":1343148,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-04T21:05:12.000Z","date":"2024-12-02","kind":"sale","planned":false,"acquired":false,"shares":1228,"price":30.37,"value":37294.36,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $30.26 to $30.46, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by ForDyne B.V. (\"ForDyne\"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 4,249,132 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5705234,"source":{"system":"sec-edgar","filing":"0000950170-24-133233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024133233/ownership.xml","form_type":"4"}},{"id":1343147,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-04T21:05:12.000Z","date":"2024-12-02","kind":"sale","planned":false,"acquired":false,"shares":79973,"price":29.66,"value":2371999.18,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $29.26 to $30.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by ForDyne B.V. (\"ForDyne\"). ForDyne is jointly owned by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion IV Management B.V. (\"Forbion Management\") may be deemed to have voting and dispositive power over 4,249,132 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5706462,"source":{"system":"sec-edgar","filing":"0000950170-24-133233","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024133233/ownership.xml","form_type":"4"}},{"id":1363892,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-15T21:05:07.000Z","date":"2024-11-14","kind":"sale","planned":true,"acquired":false,"shares":8929,"price":32.82,"value":293049.78,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $32.50 to $33.20, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held directly by ForDyne B.V. (\"ForDyne\"). ForDyne is jointly owned by FCF IV and Forbion Growth Opportunities Fund II Cooperatief U.A. (\"FGO II\"). Forbion Management may be deemed to have voting and dispositive power over 4,360,065 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"(Continued from Footnote 5) Forbion Growth II Management B.V. (\"FGO II Management\"), the director of FGO II, may be deemed to have voting and dispositive power over 1,426,370 of the shares of common stock held by ForDyne. Investment decisions with respect to the shares held by ForDyne can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. The Partners are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of ForDyne. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management. The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":5786435,"source":{"system":"sec-edgar","filing":"0000950170-24-127564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024127564/ownership.xml","form_type":"4"}},{"id":1363891,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-15T21:05:07.000Z","date":"2024-11-13","kind":"sale","planned":true,"acquired":false,"shares":10803,"price":35.24,"value":380697.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.635, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":62301,"source":{"system":"sec-edgar","filing":"0000950170-24-127564","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024127564/ownership.xml","form_type":"4"}},{"id":1383009,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T20:05:05.000Z","date":"2024-10-21","kind":"sale","planned":true,"acquired":false,"shares":121,"price":35.06,"value":4242.26,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":73104,"source":{"system":"sec-edgar","filing":"0000950170-24-116247","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024116247/ownership.xml","form_type":"4"}},{"id":1383008,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-22T20:05:05.000Z","date":"2024-10-18","kind":"sale","planned":true,"acquired":false,"shares":13414,"price":35.16,"value":471636.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":73225,"source":{"system":"sec-edgar","filing":"0000950170-24-116247","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024116247/ownership.xml","form_type":"4"}},{"id":1384175,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T20:05:05.000Z","date":"2024-10-17","kind":"sale","planned":true,"acquired":false,"shares":13013,"price":35.17,"value":457667.21,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.64, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":86639,"source":{"system":"sec-edgar","filing":"0000950170-24-115595","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024115595/ownership.xml","form_type":"4"}},{"id":1384174,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-18T20:05:05.000Z","date":"2024-10-16","kind":"sale","planned":true,"acquired":false,"shares":23671,"price":35.35,"value":836769.85,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":99652,"source":{"system":"sec-edgar","filing":"0000950170-24-115595","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024115595/ownership.xml","form_type":"4"}},{"id":1390207,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-07T20:05:03.000Z","date":"2024-10-03","kind":"sale","planned":true,"acquired":false,"shares":5441,"price":35.13,"value":191142.33,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":123323,"source":{"system":"sec-edgar","filing":"0000950170-24-113208","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024113208/ownership.xml","form_type":"4"}},{"id":1392190,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:05:03.000Z","date":"2024-10-02","kind":"sale","planned":true,"acquired":false,"shares":21518,"price":35.38,"value":761306.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.595, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":128764,"source":{"system":"sec-edgar","filing":"0000950170-24-112325","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024112325/ownership.xml","form_type":"4"}},{"id":1392189,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-03T20:05:03.000Z","date":"2024-10-01","kind":"sale","planned":true,"acquired":false,"shares":8423,"price":35.16,"value":296152.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":150282,"source":{"system":"sec-edgar","filing":"0000950170-24-112325","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024112325/ownership.xml","form_type":"4"}},{"id":1396840,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T20:05:04.000Z","date":"2024-09-30","kind":"sale","planned":true,"acquired":false,"shares":1935,"price":36.02,"value":69698.7,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $36.005 to $36.04, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":158705,"source":{"system":"sec-edgar","filing":"0000950170-24-110797","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024110797/ownership.xml","form_type":"4"}},{"id":1396839,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T20:05:04.000Z","date":"2024-09-30","kind":"sale","planned":true,"acquired":false,"shares":29007,"price":35.47,"value":1028878.29,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":160640,"source":{"system":"sec-edgar","filing":"0000950170-24-110797","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024110797/ownership.xml","form_type":"4"}},{"id":1396838,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-01T20:05:04.000Z","date":"2024-09-27","kind":"sale","planned":true,"acquired":false,"shares":32,"price":35,"value":1120.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":189647,"source":{"system":"sec-edgar","filing":"0000950170-24-110797","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024110797/ownership.xml","form_type":"4"}},{"id":1398523,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:05:04.000Z","date":"2024-09-26","kind":"sale","planned":true,"acquired":false,"shares":1260,"price":35.29,"value":44465.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.10 to $35.46, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":189679,"source":{"system":"sec-edgar","filing":"0000950170-24-109994","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024109994/ownership.xml","form_type":"4"}},{"id":1398522,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-27T20:05:04.000Z","date":"2024-09-25","kind":"sale","planned":true,"acquired":false,"shares":2357,"price":35.06,"value":82636.42,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.215, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":190939,"source":{"system":"sec-edgar","filing":"0000950170-24-109994","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024109994/ownership.xml","form_type":"4"}},{"id":1400185,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-24T20:05:03.000Z","date":"2024-09-23","kind":"sale","planned":true,"acquired":false,"shares":4610,"price":36.33,"value":167481.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $36.015 to $36.66, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":193296,"source":{"system":"sec-edgar","filing":"0000950170-24-109068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024109068/ownership.xml","form_type":"4"}},{"id":1400184,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-24T20:05:03.000Z","date":"2024-09-23","kind":"sale","planned":true,"acquired":false,"shares":36221,"price":35.19,"value":1274616.99,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.895, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":197906,"source":{"system":"sec-edgar","filing":"0000950170-24-109068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024109068/ownership.xml","form_type":"4"}},{"id":1400183,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-24T20:05:03.000Z","date":"2024-09-20","kind":"sale","planned":true,"acquired":false,"shares":471,"price":37.01,"value":17431.71,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $37.00 to $37.01, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":234127,"source":{"system":"sec-edgar","filing":"0000950170-24-109068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024109068/ownership.xml","form_type":"4"}},{"id":1400182,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-24T20:05:03.000Z","date":"2024-09-20","kind":"sale","planned":true,"acquired":false,"shares":78940,"price":36.45,"value":2877363.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $36.00 to $36.995, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":234598,"source":{"system":"sec-edgar","filing":"0000950170-24-109068","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024109068/ownership.xml","form_type":"4"}},{"id":1401673,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-20T20:05:02.000Z","date":"2024-09-19","kind":"sale","planned":true,"acquired":false,"shares":50972,"price":36.41,"value":1855890.52,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $36.06 to $37.03, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":313538,"source":{"system":"sec-edgar","filing":"0000950170-24-108403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024108403/ownership.xml","form_type":"4"}},{"id":1401672,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-20T20:05:02.000Z","date":"2024-09-19","kind":"sale","planned":true,"acquired":false,"shares":27767,"price":35.74,"value":992392.58,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.06 to $36.058, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":364510,"source":{"system":"sec-edgar","filing":"0000950170-24-108403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024108403/ownership.xml","form_type":"4"}},{"id":1401671,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-20T20:05:02.000Z","date":"2024-09-18","kind":"sale","planned":true,"acquired":false,"shares":1554,"price":35.03,"value":54436.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":392277,"source":{"system":"sec-edgar","filing":"0000950170-24-108403","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024108403/ownership.xml","form_type":"4"}},{"id":1403704,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T20:05:04.000Z","date":"2024-09-17","kind":"sale","planned":true,"acquired":false,"shares":3272,"price":35.13,"value":114945.36,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.22, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":393831,"source":{"system":"sec-edgar","filing":"0000950170-24-107768","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024107768/ownership.xml","form_type":"4"}},{"id":1403703,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-18T20:05:04.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":1320,"price":35.04,"value":46252.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":397103,"source":{"system":"sec-edgar","filing":"0000950170-24-107768","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024107768/ownership.xml","form_type":"4"}},{"id":1411898,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-09T20:05:07.000Z","date":"2024-09-05","kind":"sale","planned":true,"acquired":false,"shares":1577,"price":35.03,"value":55242.31,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $35.00 to $35.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":398423,"source":{"system":"sec-edgar","filing":"0000950170-24-104738","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024104738/ownership.xml","form_type":"4"}},{"id":1415911,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-04T20:05:03.000Z","date":"2024-08-30","kind":"sale","planned":true,"acquired":false,"shares":6204,"price":46.01,"value":285446.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.89 to $46.26, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":400000,"source":{"system":"sec-edgar","filing":"0000950170-24-103382","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103382/ownership.xml","form_type":"4"}},{"id":1415910,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-04T20:05:03.000Z","date":"2024-08-30","kind":"sale","planned":true,"acquired":false,"shares":25096,"price":45.49,"value":1141617.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.885 to $45.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":406204,"source":{"system":"sec-edgar","filing":"0000950170-24-103382","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103382/ownership.xml","form_type":"4"}},{"id":1419053,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-30T20:05:13.000Z","date":"2024-08-29","kind":"sale","planned":true,"acquired":false,"shares":10768,"price":45.81,"value":493282.08,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.66 to $46.03, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":431300,"source":{"system":"sec-edgar","filing":"0000950170-24-102326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024102326/ownership.xml","form_type":"4"}},{"id":1419052,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-30T20:05:13.000Z","date":"2024-08-29","kind":"sale","planned":true,"acquired":false,"shares":45640,"price":45.19,"value":2062471.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.65 to $45.63, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":442068,"source":{"system":"sec-edgar","filing":"0000950170-24-102326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024102326/ownership.xml","form_type":"4"}},{"id":1419051,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-30T20:05:13.000Z","date":"2024-08-28","kind":"sale","planned":true,"acquired":false,"shares":61467,"price":44.94,"value":2762326.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.76 to $45.11, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":487708,"source":{"system":"sec-edgar","filing":"0000950170-24-102326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024102326/ownership.xml","form_type":"4"}},{"id":1419050,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-30T20:05:13.000Z","date":"2024-08-28","kind":"sale","planned":true,"acquired":false,"shares":16386,"price":44.41,"value":727702.26,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.76 to $44.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":549175,"source":{"system":"sec-edgar","filing":"0000950170-24-102326","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024102326/ownership.xml","form_type":"4"}},{"id":1420979,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-28T20:05:04.000Z","date":"2024-08-27","kind":"sale","planned":true,"acquired":false,"shares":65403,"price":44.28,"value":2896044.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.79 to $44.67, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":565561,"source":{"system":"sec-edgar","filing":"0000950170-24-101378","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024101378/ownership.xml","form_type":"4"}},{"id":1420978,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-28T20:05:04.000Z","date":"2024-08-26","kind":"sale","planned":true,"acquired":false,"shares":11534,"price":45.79,"value":528141.86,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.71 to $46.16, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":630964,"source":{"system":"sec-edgar","filing":"0000950170-24-101378","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024101378/ownership.xml","form_type":"4"}},{"id":1420977,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-28T20:05:04.000Z","date":"2024-08-26","kind":"sale","planned":true,"acquired":false,"shares":77963,"price":45.23,"value":3526266.49,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.71 to $45.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":642498,"source":{"system":"sec-edgar","filing":"0000950170-24-101378","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024101378/ownership.xml","form_type":"4"}},{"id":1423351,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T20:05:06.000Z","date":"2024-08-23","kind":"sale","planned":true,"acquired":false,"shares":64133,"price":46.37,"value":2973847.21,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.14 to $46.76, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":720461,"source":{"system":"sec-edgar","filing":"0000950170-24-100532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024100532/ownership.xml","form_type":"4"}},{"id":1423350,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T20:05:06.000Z","date":"2024-08-23","kind":"sale","planned":true,"acquired":false,"shares":20955,"price":45.82,"value":960158.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.14 to $46.13, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":784594,"source":{"system":"sec-edgar","filing":"0000950170-24-100532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024100532/ownership.xml","form_type":"4"}},{"id":1423349,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T20:05:06.000Z","date":"2024-08-22","kind":"sale","planned":true,"acquired":false,"shares":413,"price":46.97,"value":19398.61,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.76 to $47.06, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":805549,"source":{"system":"sec-edgar","filing":"0000950170-24-100532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024100532/ownership.xml","form_type":"4"}},{"id":1423348,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-26T20:05:06.000Z","date":"2024-08-22","kind":"sale","planned":true,"acquired":false,"shares":94908,"price":45.82,"value":4348684.56,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.45 to $46.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":805962,"source":{"system":"sec-edgar","filing":"0000950170-24-100532","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024100532/ownership.xml","form_type":"4"}},{"id":1425470,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-22T20:05:03.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":71245,"price":47.01,"value":3349227.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.86 to $47.34, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":900870,"source":{"system":"sec-edgar","filing":"0000950170-24-099831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099831/ownership.xml","form_type":"4"}},{"id":1425469,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-22T20:05:03.000Z","date":"2024-08-21","kind":"sale","planned":true,"acquired":false,"shares":64518,"price":46.52,"value":3001377.36,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.86 to $46.85, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":972115,"source":{"system":"sec-edgar","filing":"0000950170-24-099831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099831/ownership.xml","form_type":"4"}},{"id":1425468,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-22T20:05:03.000Z","date":"2024-08-20","kind":"sale","planned":true,"acquired":false,"shares":8326,"price":47.3,"value":393819.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $47.25 to $47.38, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1036633,"source":{"system":"sec-edgar","filing":"0000950170-24-099831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099831/ownership.xml","form_type":"4"}},{"id":1425467,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-22T20:05:03.000Z","date":"2024-08-20","kind":"sale","planned":true,"acquired":false,"shares":35457,"price":46.94,"value":1664351.58,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.25 to $47.24, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1044959,"source":{"system":"sec-edgar","filing":"0000950170-24-099831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099831/ownership.xml","form_type":"4"}},{"id":1425466,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-22T20:05:03.000Z","date":"2024-08-20","kind":"sale","planned":true,"acquired":false,"shares":43057,"price":45.68,"value":1966843.76,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.21 to $46.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1080416,"source":{"system":"sec-edgar","filing":"0000950170-24-099831","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099831/ownership.xml","form_type":"4"}},{"id":1427800,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:05:04.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":5760,"price":46.59,"value":268358.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.55 to $46.64, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1123473,"source":{"system":"sec-edgar","filing":"0000950170-24-099071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099071/ownership.xml","form_type":"4"}},{"id":1427799,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:05:04.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":89824,"price":46.01,"value":4132802.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.55 to $46.54, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1129233,"source":{"system":"sec-edgar","filing":"0000950170-24-099071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099071/ownership.xml","form_type":"4"}},{"id":1427798,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:05:04.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":30448,"price":45.1,"value":1373204.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.55 to $45.54, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1219057,"source":{"system":"sec-edgar","filing":"0000950170-24-099071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099071/ownership.xml","form_type":"4"}},{"id":1427797,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:05:04.000Z","date":"2024-08-16","kind":"sale","planned":true,"acquired":false,"shares":3072,"price":46.19,"value":141895.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $46.13 to $46.20, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1249505,"source":{"system":"sec-edgar","filing":"0000950170-24-099071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099071/ownership.xml","form_type":"4"}},{"id":1427796,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:05:04.000Z","date":"2024-08-16","kind":"sale","planned":true,"acquired":false,"shares":85086,"price":45.35,"value":3858650.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.01 to $45.99, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1252577,"source":{"system":"sec-edgar","filing":"0000950170-24-099071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099071/ownership.xml","form_type":"4"}},{"id":1427795,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-20T20:05:04.000Z","date":"2024-08-16","kind":"sale","planned":true,"acquired":false,"shares":34485,"price":44.52,"value":1535272.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.00 to $44.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1337663,"source":{"system":"sec-edgar","filing":"0000950170-24-099071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024099071/ownership.xml","form_type":"4"}},{"id":1431443,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-16T20:05:09.000Z","date":"2024-08-15","kind":"sale","planned":true,"acquired":false,"shares":49601,"price":45.67,"value":2265277.67,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $45.56 to $45.89, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1372148,"source":{"system":"sec-edgar","filing":"0000950170-24-098052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024098052/ownership.xml","form_type":"4"}},{"id":1431442,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-16T20:05:09.000Z","date":"2024-08-15","kind":"sale","planned":true,"acquired":false,"shares":131290,"price":45.25,"value":5940872.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $44.56 to $45.55, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1421749,"source":{"system":"sec-edgar","filing":"0000950170-24-098052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024098052/ownership.xml","form_type":"4"}},{"id":1431441,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-16T20:05:09.000Z","date":"2024-08-14","kind":"sale","planned":true,"acquired":false,"shares":100650,"price":43.67,"value":4395385.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.23 to $44.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1553039,"source":{"system":"sec-edgar","filing":"0000950170-24-098052","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024098052/ownership.xml","form_type":"4"}},{"id":1433829,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:15:05.000Z","date":"2024-08-13","kind":"sale","planned":true,"acquired":false,"shares":21428,"price":43.57,"value":933617.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.26 to $44.24, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1653689,"source":{"system":"sec-edgar","filing":"0000950170-24-097031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024097031/ownership.xml","form_type":"4"}},{"id":1433828,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:15:05.000Z","date":"2024-08-13","kind":"sale","planned":true,"acquired":false,"shares":88179,"price":42.78,"value":3772297.62,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.25 to $43.24, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1675117,"source":{"system":"sec-edgar","filing":"0000950170-24-097031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024097031/ownership.xml","form_type":"4"}},{"id":1433827,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:15:05.000Z","date":"2024-08-13","kind":"sale","planned":true,"acquired":false,"shares":24378,"price":42.08,"value":1025826.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.95 to $42.23, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1763296,"source":{"system":"sec-edgar","filing":"0000950170-24-097031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024097031/ownership.xml","form_type":"4"}},{"id":1433826,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:15:05.000Z","date":"2024-08-12","kind":"sale","planned":true,"acquired":false,"shares":52076,"price":43.42,"value":2261139.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.105 to $44.09, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1787674,"source":{"system":"sec-edgar","filing":"0000950170-24-097031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024097031/ownership.xml","form_type":"4"}},{"id":1433825,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:15:05.000Z","date":"2024-08-12","kind":"sale","planned":true,"acquired":false,"shares":26416,"price":42.74,"value":1129019.84,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.09 to $43.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1839750,"source":{"system":"sec-edgar","filing":"0000950170-24-097031","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024097031/ownership.xml","form_type":"4"}},{"id":1433824,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:05:06.000Z","date":"2024-08-09","kind":"sale","planned":true,"acquired":false,"shares":1160,"price":44.04,"value":51086.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.995 to $44.06, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1866166,"source":{"system":"sec-edgar","filing":"0000950170-24-096987","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024096987/ownership.xml","form_type":"4/A","original_submission_date":"2024-08-12"}},{"id":1433823,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:05:06.000Z","date":"2024-08-09","kind":"sale","planned":true,"acquired":false,"shares":40268,"price":43.44,"value":1749241.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.99 to $43.98, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1867326,"source":{"system":"sec-edgar","filing":"0000950170-24-096987","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024096987/ownership.xml","form_type":"4/A","original_submission_date":"2024-08-12"}},{"id":1433822,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:05:06.000Z","date":"2024-08-09","kind":"sale","planned":true,"acquired":false,"shares":50736,"price":42.55,"value":2158816.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.985 to $42.98, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1907594,"source":{"system":"sec-edgar","filing":"0000950170-24-096987","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024096987/ownership.xml","form_type":"4/A","original_submission_date":"2024-08-12"}},{"id":1433821,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:05:06.000Z","date":"2024-08-08","kind":"sale","planned":true,"acquired":false,"shares":68936,"price":42.87,"value":2955286.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.465 to $43.23, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1958330,"source":{"system":"sec-edgar","filing":"0000950170-24-096987","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024096987/ownership.xml","form_type":"4/A","original_submission_date":"2024-08-12"}},{"id":1433820,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:05:06.000Z","date":"2024-08-08","kind":"sale","planned":true,"acquired":false,"shares":16357,"price":42.97,"value":702860.29,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.605 to $42.435, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":2027266,"source":{"system":"sec-edgar","filing":"0000950170-24-096987","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024096987/ownership.xml","form_type":"4/A","original_submission_date":"2024-08-12"}},{"id":1433819,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-14T20:05:06.000Z","date":"2024-08-08","kind":"sale","planned":true,"acquired":false,"shares":6377,"price":40.74,"value":259798.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $40.60 to $41.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":2043623,"source":{"system":"sec-edgar","filing":"0000950170-24-096987","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024096987/ownership.xml","form_type":"4/A","original_submission_date":"2024-08-12"}},{"id":1436084,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T20:05:04.000Z","date":"2024-08-09","kind":"sale","planned":true,"acquired":false,"shares":1160,"price":44.04,"value":51086.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $43.995 to $44.06, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":6232959,"source":{"system":"sec-edgar","filing":"0000950170-24-095402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024095402/ownership.xml","form_type":"4"}},{"id":1436083,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T20:05:04.000Z","date":"2024-08-09","kind":"sale","planned":true,"acquired":false,"shares":40268,"price":43.44,"value":1749241.92,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.99 to $43.98, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":6234119,"source":{"system":"sec-edgar","filing":"0000950170-24-095402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024095402/ownership.xml","form_type":"4"}},{"id":1436082,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T20:05:04.000Z","date":"2024-08-09","kind":"sale","planned":true,"acquired":false,"shares":50736,"price":42.55,"value":2158816.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.985 to $42.98, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":6274387,"source":{"system":"sec-edgar","filing":"0000950170-24-095402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024095402/ownership.xml","form_type":"4"}},{"id":1436081,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T20:05:04.000Z","date":"2024-08-08","kind":"sale","planned":true,"acquired":false,"shares":68936,"price":42.87,"value":2955286.32,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $42.465 to $43.23, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":6325123,"source":{"system":"sec-edgar","filing":"0000950170-24-095402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024095402/ownership.xml","form_type":"4"}},{"id":1436080,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T20:05:04.000Z","date":"2024-08-08","kind":"sale","planned":true,"acquired":false,"shares":16357,"price":42.97,"value":702860.29,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $41.605 to $42.435, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":6394059,"source":{"system":"sec-edgar","filing":"0000950170-24-095402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024095402/ownership.xml","form_type":"4"}},{"id":1436079,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-08-12T20:05:04.000Z","date":"2024-08-08","kind":"sale","planned":true,"acquired":false,"shares":6377,"price":40.74,"value":259798.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Forbion Capital Fund IV Cooperatief U.A. (\"FCF IV\") on April 9, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $40.60 to $41.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held directly by FCF IV. Forbion IV Management B.V. (\"Forbion Management\"), the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":6410416,"source":{"system":"sec-edgar","filing":"0000950170-24-095402","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024095402/ownership.xml","form_type":"4"}},{"id":1502167,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2024-05-24T21:10:21.000Z","date":"2024-05-22","kind":"grant","planned":false,"acquired":true,"shares":25133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 22, 2024. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 22, 2025 or (ii) the date of the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service."}],"balance_after":25133,"derivative":{"exercise_price":31.53,"expiration_date":"2034-05-21","underlying":"Common Stock","underlying_shares":25133},"source":{"system":"sec-edgar","filing":"0000950170-24-064728","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024064728/ownership.xml","form_type":"4"}},{"id":1680833,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-11T21:31:55.000Z","date":"2024-01-09","kind":"purchase","planned":false,"acquired":true,"shares":1428571,"price":17.5,"value":24999992.5,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held directly by Forbion Growth Opportunities Fund II Cooperatief U.A (\"FGO II \"). Forbion Growth II Management B.V. (\"FGO II Management\") the director of FGO II, may be deemed to have voting and dispositive power over the shares held by FGO II. Investment decisions with respect to the shares held by FGO II can be made by FCPM III Services B.V., the director of FGO II Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of FGO II Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FGO II. The Reporting Person is a partner of FGO II Management and a member of the investment committee of FGO II Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":1428571,"source":{"system":"sec-edgar","filing":"0000950170-24-003943","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024003943/ownership.xml","form_type":"4"}},{"id":1680832,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-01-11T21:31:55.000Z","date":"2024-01-09","kind":"purchase","planned":false,"acquired":true,"shares":285714,"price":17.5,"value":4999995.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The shares are held directly by Forbion Capital Fund IV Cooperatief U.A (\"FCF IV\"). Forbion IV Management B.V. (\"Forbion Management\") the director of FCF IV, may be deemed to have voting and dispositive power over the shares held by FCF IV. Investment decisions with respect to the shares held by FCF IV can be made by FCPM III Services B.V., the director of Forbion Management, which may delegate such powers to its investment committee which may delegate such powers to the authorized representatives of Forbion Management. Messrs. Slootweg, van Osch, Mulder, van Houten, Reithinger and Boorsma (the \"Partners\") are partners of FCPM III Services B.V., which acts as the investment advisor to the directors of FCF IV. The Reporting Person is a partner of Forbion Management and a member of the investment committee of Forbion Management.  The Reporting Person disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest therein."}],"balance_after":6416793,"source":{"system":"sec-edgar","filing":"0000950170-24-003943","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024003943/ownership.xml","form_type":"4"}},{"id":1878265,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":28035,"kind":"person","name":"Kersten Dirk","position":1,"cik":"0001823682","reported_name":"Kersten Dirk","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-05-25T22:37:32.000Z","date":"2023-05-24","kind":"grant","planned":false,"acquired":true,"shares":24900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 24, 2023. The shares underlying the option are scheduled to vest in full on the earlier of (i) May 24, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders."}],"balance_after":24900,"derivative":{"exercise_price":13.49,"expiration_date":"2033-05-23","underlying":"Common Stock","underlying_shares":24900},"source":{"system":"sec-edgar","filing":"0001209191-23-032276","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000120919123032276/doc4.xml","form_type":"4"}}],"next_cursor":"2023-05-25T22:37:32.000000Z,1878265"}